EAGLE-1 trial data shows gepotidacin’s potential in treating gonorrhoea, for which no new antibiotics have been approved ...

If you’re on the fence about investing in TechnipFMC plc, Patterson-UTI Energy or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your ...

HOUSTON, TX / ACCESS Newswire / April 7, 2025 / PATTERSON-UTI ENERGY, INC. (NASDAQ:PTEN) will host a conference call on Thursday, April 24, 2025, at 9:00 a.m. Central Time to discuss results for ...

The US Food and Drug Administration (FDA) recently approved Blujepa (gepotidacin), a ground-breaking oral antibiotic for treating uncomplicated urinary tract infections (UTIs). This is the first new ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were randomly ...

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...

Urinary tract infections (UTIs) are among the most common bacterial infections, affecting millions worldwide. However, the increasing resistance of bacteria to standard antibiotics has made ...

Urinary tract infections in patients with neurogenic bladder are highly ... Studies have confirmed that specific bacterial genera, such as Lactobacillus and Enterococcus, may be microbiological ...

Staphylococcus saprophyticus and Enterococcus faecalis. More than half of all women will contract this kind of UTI in their lifetime, and almost a third will battle recurring episodes. Blujepa ...

The FDA has approved GSK’s gepotidacin (Blujepa) for uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older. The small-molecule drug is ...

If sold after 1 year from purchase date, long term capital gain tax will be applicable. Current tax rate is 12.5%, if your total long term capital gain exceeds 1.25 lakh. Any cess/surcharge is not ...